Related Experiment Video
Updated: Apr 23, 2026

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
Published on: March 11, 2017
Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms
Insights
A new, easy-to-make oral liquid formulation of cilazapril (1 mg/mL) has been developed for pediatric heart failure patients. This stable and palatable suspension maintains its quality for 28 days at room temperature.
Area of Science:
- Pharmaceutical Sciences
- Pediatric Pharmacology
- Drug Formulation
Background:
- Cilazapril is essential for managing pediatric heart failure.
- Current tablet forms are unsuitable for children.
- No oral liquid cilazapril formulations have been previously studied.
Purpose of the Study:
- To develop an easy-to-prepare, palatable oral liquid cilazapril formulation (1 mg/mL).
- To assess the physicochemical stability of this pediatric formulation.
- To evaluate formulation stability using original and generic cilazapril tablets and various packaging.
Main Methods:
- Compounding cilazapril suspensions using Ora-Blend" suspending agent.
- Chemical stability assessed via HPLC.
- Physical stability evaluated through appearance, taste, smell, pH, and rheological tests.
- Storage in amber glass or PET bottles at 298 K for 28 days.
Main Results:
- Cilazapril oral suspensions (1 mg/mL) showed satisfactory stability over 28 days at room temperature.
- Cilazapril concentrations remained within acceptable limits (+/- 10%).
- Physical properties of the suspensions were unaffected during storage.
Conclusions:
- Cilazapril-Ora-Blend* pediatric oral liquid is easy to prepare, palatable, and stable for 28 days at room temperature.
- Formulation stability is consistent regardless of cilazapril tablet manufacturer or bottle type (glass/PET).
- This formulation offers a viable alternative for pediatric cilazapril administration.
Abstract:
Abstract: Cilazapril is a drug commonly used in management of heart failure in pediatric population. On pharmaceutical market it is available only in inconvenient for pediatric use tablet dosage forms. Until now, no oral liquid formulation containing cilazapril has been evaluated. Therefore, the aim of this study was to prepare easy to made and palatable 1 mg/mL oral liquid formulation with cilazapril (with consideration of original and generic cilazapril tablet and different packages) and subsequent investigation of physicochemical stability of these suspensions. Formulations were compounded using cilazapril obtained from original or generic cilazapril marketed tablet formulations and Ora-Blend" suspending agent. Stability of prepared suspensions stored in closed amber glass or amber plastic PET bottles in the temperature of 298 K was estimated throughout 28 day shelf-life period. Chemical stability was assessed by HPLC cilazapril stability indicating method. Physical stability was evaluated by appearance, taste, smell, pH and theological assessments. Cilazapril oral suspensions at concentration of 1 mg/mL demonstrated satisfactory stability over 28 day long storage at room temperature. Cilazapril concentrations remained within acceptable limit (+/- 10%) stored in closed amber bottles made of glass or PET material. Moreover, suspensions physical properties remained unaffected. Cilazapril - Ora-Blend* pediatric oral liquid is easy to made, palatable and stable when stored at room temperature for 28 days. Stability of cilazapril oral liquid remains unchanged while using cilazapril tablets produced by different manufacturers and bottles made of amber glass or PET material.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Dosing: Infants and Children

